Sun Pharma Crashes 4% After Q4 Profit Slumps 19% — What’s Next for the Stock?

shares fell over 4% in morning trade on May 23, 2025 (till 9:25AM), after the company reported a 19% year-on-year decline in Q4FY25 net profit to ₹2,153.93 crore. Despite the profit dip, total revenue rose 8% YoY to ₹12,958.84 crore, and EBITDA grew 22% to ₹3,716 crore, reflecting operational strength. The company also declared a dividend of ₹5.50 per share. Technically, ₹1,620 may serve as immediate support, while ₹1,553 is likely to act as a crucial long-term support level. The sharp stock reaction indicates investor concern over the earnings decline despite strong top-line and EBITDA performance. Disclaimer: This post is for informational purposes only and does not constitute trading or investment advice.